Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China.
Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China.
World J Surg Oncol. 2019 Jul 3;17(1):114. doi: 10.1186/s12957-019-1658-9.
Postsurgical patients' oral feeding begins with clear fluids 1-3 days after surgery. This might not be sufficiently nutritious to boost the host immune system and provide sufficient energy in gastric neoplastic patients to achieve the goal of enhanced recovery after surgery (ERAS). Our objective was to analyze the significance of early postoperative feeding tubes in boosting patients' immunity and decreasing incidence of overall complications and hospital stay in gastric cancer patients' post-gastrectomy.
From January 2005 to May 24, 2019, PubMed and Cochrane databases were searched for studies involving enteral nutrition (EN) feeding tubes in comparison to parenteral nutrition (PN) in gastric cancer patients undergoing gastrectomy for gastric malignancies. Relative risk (RR), mean difference (MD), or standard mean difference (SMD) with 95% confidence interval (CI) were used to estimate the effect sizes, and heterogeneity was assessed by using Q and χ statistic with their corresponding P values. All the analyses were performed with Review Manager 5.3 and SPSS version 22.
Nine randomized trials (n = 1437) and 5 retrospective studies (n = 421) comparing EN feeding tubes and PN were deemed eligible for the pooled analyses, with a categorized time frame of PODs ≥ 7 and PODs < 7. Ratio of CD4+/CD8+ in EN feeding tubes was the only outcome of PODs < 7, which showed significance (MD 0.22, 95% CI 0.18-0.25, P < 0.00001). Regarding other immune indicators, significant outcomes in favor of EN feeding tubes were measured on POD ≥ 7: CD3+ (SMD 1.71; 95% CI 0.70, 2.72; P = 0.0009), CD4+ (MD 5.84; 95% CI 4.19, 7.50; P < 0.00001), CD4+/CD8+ (MD 0.28; 95% CI 0.20; 0.36, P < 0.00001), NK cells (SMD 0.94; 95% CI 0.54, 1.30; P < 0.00001), nutrition values, albumin (SMD 0.63; 95% CI 0.34, 0.91; P < 0.001), prealbumin (SMD 1.00; 95% CI 0.52, 1.48; P < 0.00001), and overall complications (risk ratio 0.73 M-H; fixed; 95% CI 0.58, 0.92; P = 0.006).
EN feeding tube support is an essential intervention to elevate patients' immunity, depress levels of inflammation, and reduce the risk of complications after gastrectomy for gastric cancer. Enteral nutrition improves the innate immune system and nutrition levels but has no marked significance on certain clinical outcomes. Also, EN reduces the duration of hospital stay and cost, significantly.
术后患者的口服喂养从手术后 1-3 天开始食用清液。对于胃肿瘤患者,这可能不足以促进宿主的免疫系统,提供足够的能量,以达到术后加速康复(ERAS)的目标。我们的目的是分析早期术后喂养管在增强患者免疫力和降低胃癌患者术后总体并发症发生率和住院时间方面的意义。
从 2005 年 1 月至 2019 年 5 月 24 日,检索了PubMed 和 Cochrane 数据库中涉及胃癌患者胃切除术后肠内营养(EN)喂养管与肠外营养(PN)比较的研究。使用相对风险(RR)、均数差(MD)或标准均数差(SMD)和 95%置信区间(CI)来估计效应大小,并使用 Q 和 χ 统计量及其相应的 P 值评估异质性。所有分析均使用 Review Manager 5.3 和 SPSS 版本 22 进行。
9 项随机试验(n=1437)和 5 项回顾性研究(n=421)符合纳入荟萃分析的标准,分为术后第 7 天及以上(PODs≥7)和术后第 7 天及以下(PODs<7)两个时间框架。EN 喂养管唯一的术后第 7 天及以下的 CD4+/CD8+比值是有意义的(MD 0.22,95%CI 0.18-0.25,P<0.00001)。至于其他免疫指标,EN 喂养管在术后第 7 天及以上的显著结果包括:CD3+(SMD 1.71;95%CI 0.70,2.72;P=0.0009)、CD4+(MD 5.84;95%CI 4.19,7.50;P<0.00001)、CD4+/CD8+(MD 0.28;95%CI 0.20,0.36,P<0.00001)、NK 细胞(SMD 0.94;95%CI 0.54,1.30;P<0.00001)、营养值、白蛋白(SMD 0.63;95%CI 0.34,0.91;P<0.001)、前白蛋白(SMD 1.00;95%CI 0.52,1.48;P<0.00001)和总体并发症(风险比 0.73 M-H;固定;95%CI 0.58,0.92;P=0.006)。
EN 喂养管支持是提高患者免疫力、降低炎症水平和降低胃癌胃切除术后并发症风险的重要干预措施。肠内营养可改善固有免疫系统和营养水平,但对某些临床结局无明显意义。此外,EN 还显著降低了住院时间和成本。